AI in antibody discovery refers to the application of advanced computational technologies such as machine learning (ML), deep learning, generative AI, and antibody-specific large language models (LLMs) to streamline and optimize the discovery and development of therapeutic antibodies. These technologies enhance processes such as target identification, lead generation, binding affinity prediction, developability assessment, and candidate optimization.
Traditional antibody discovery approaches are often slow, resource-intensive, and associated with high failure rates. AI-powered platforms significantly reduce development timelines, improve prediction accuracy, and increase the probability of clinical success. By integrating AI with multi-omics data, structural biology insights, and high-throughput screening systems, organizations can design more precise and personalized antibody therapies.
According to BIS Research, the Europe AI in antibody discovery market was valued at $153.8 million in 2025 and is projected to reach $1,438.4 million by 2035, growing at a CAGR of 25.05% during the forecast period 2025-2035, reflecting strong momentum in AI-enabled biologics innovation across the region.
Download the complete TOC and Request Sample Report
• Strong biopharma R&D ecosystem across the UK, Germany, France, and Switzerland
• Rising need to reduce development timelines and high attrition rates in traditional antibody discovery
• Growing adoption of AI-led autonomous discovery platforms for iterative design-test-optimize cycles
• Increased integration of generative AI and antibody-specific LLMs for predictive modeling and candidate design
• Expanding public and private funding initiatives supporting AI-biotech innovation
• Strategic collaborations between AI startups, CROs, academic institutions, and pharmaceutical companies
• Growing adoption of AI-driven discovery platforms for faster early-stage lead identification
• Hybrid workflows combining in-silico modeling with automated wet-lab validation
• Use of predictive models for binding affinity, developability, and immunogenicity assessment
• Expansion of personalized and precision antibody therapies targeting oncology, autoimmune, and rare diseases
• Rising interest in advanced modalities such as bispecific antibodies and antibody-drug conjugates supported by computational design
• Increasing availability of cloud-based, consulting-led, and on-premise AI solutions to improve accessibility
• Complex regulatory landscape and strict data privacy requirements across Europe
• Difficulty in validating AI-generated predictions to meet regulatory standards for drug development
• Limited access to large, standardized, high-quality labeled datasets
• Fragmented and proprietary data limiting model generalizability
• Cautious investment climate for deep computational biotech compared to other regions
• Shortage of interdisciplinary talent combining AI, structural biology, and immunology expertise
• High computational infrastructure costs, including HPC and cloud resources
• Increasing partnerships between AI-focused biotech startups and established pharmaceutical companies to accelerate clinical validation and commercialization
• Expansion of cross-border research consortia and innovation clusters promoting shared AI tools and talent exchange
• Growth in contract research and platform-based collaborations to scale AI-powered antibody discovery services
• Integration of generative AI with multi-omics datasets to enable more precise and customized therapeutic antibody development
• Continued regional funding programs supporting AI-driven life sciences innovation
According to Principal Analyst at BIS Research: “The Europe AI in antibody discovery market is poised for robust expansion as pharmaceutical and biotech companies increasingly integrate generative AI and advanced predictive models into their R&D pipelines. The shift toward autonomous, AI-enabled discovery platforms will significantly enhance efficiency, reduce costs, and improve clinical success rates. With strong regional research infrastructure and growing cross-sector collaborations, Europe is emerging as a leading hub for AI-driven biologics innovation.”
The market is projected to grow from $153.8 million in 2025 to $1,438.4 million by 2035, at a CAGR of 25.05%, driven by accelerating AI adoption in antibody discovery workflows.
Key players include LabGenius Therapeutics, Antiverse, EVQLV, Inc., MAbsillco, and Cradle Bio B.V., along with partnerships involving major pharmaceutical companies and CROs.
Generative AI, deep learning, and antibody-specific LLMs are gaining strong traction due to their ability to improve target identification, optimize developability parameters, and accelerate candidate selection.
Europe benefits from strong pharmaceutical infrastructure, advanced academic research networks, supportive public funding programs, and active cross-border collaborations, all of which foster innovation and commercialization.
BIS Research provides expert-driven insights, granular segmentation, and strategic advisory across biotechnology, healthcare AI, and advanced therapeutics domains.
